Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 66, Issue 4, pp 721–728 | Cite as

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer

  • Yasushi Sato
  • Tetsuji Takayama
  • Tamotsu Sagawa
  • Yasuo Takahashi
  • Hiroyuki Ohnuma
  • Syunichi Okubo
  • Naoaki Shintani
  • Shingo Tanaka
  • Masaya Kida
  • Yasuhiro Sato
  • Hidetoshi Ohta
  • Koji Miyanishi
  • Tsutomu Sato
  • Rishu Takimoto
  • Masayoshi Kobune
  • Koji Yamaguchi
  • Koichi Hirata
  • Yoshiro Niitsu
  • Junji Kato
Original Article

Abstract

Purpose

We evaluated the activity and toxicity of docetaxel, cisplatin, and S-1 (DCS) combination chemotherapy in patients with unresectable metastatic gastric cancer.

Methods

Patients with histologically proven, unresectable metastatic gastric adenocarcinoma, performance status (PS) 0–2, and no prior chemotherapy were eligible. Patients received oral S-1 (40 mg/m2 b.i.d.) on days 1–14 and intravenous cisplatin (60 mg/m2) and docetaxel (60 mg/m2) on day 8 every 3 weeks.

Results

Thirty-four patients were enrolled between March 2005 and April 2007. Three patients were considered ineligible and did not receive the DSC therapy. Clinical characteristics were as follows: median age, 63 years (range, 44–77); PS, 0/1/2: 23/8/0; women/men, 8/23; and well-differentiated/undifferentiated adenocarcinoma, 10/21. The objective response rate was 87.1% with 1 complete response (3.2%) and 26 partial responses (83.9%) in 31 assessable patients. Four had stable disease (12.9%) but none had progressive disease. Of these 27 responders, 8 (25.8%) achieved downstaging and 7 (22.6%) underwent curative surgery. The median survival time and progression-free survival were 687 days [confidence interval (95% CI), 600.0–1,138.1] and 226 days (95% CI, 182.5–379.3), respectively. Most common grade 3/4 hematologic toxicity was neutropenia (77.4%). Most common grade 3 nonhematologic toxicities included anorexia (35.5%) and nausea (32.3%). All treatment-related toxicities resolved, and no toxic deaths were observed.

Conclusions

DCS combination chemotherapy is highly active against unresectable metastatic gastric cancer and can be given safely with proper management of adverse events. Further studies of this combination are warranted.

Keywords

Gastric cancer Docetaxel Cisplatin S-1 Chemotherapy 

Notes

Acknowledgments

We thank the following doctors for their assistance in this study. Hiroyuki Nagashima, M.D., Gangi Kuroiwa, M.D., Michiaki Hirayama, M.D., Shinichi Katsuki, M.D., Hiroshi Muramatsu, M.D., Hiroyuki Kuroda, M.D., Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine, Sapporo, Japan and Tomoko Sonoda, M.D., Department of Public Health, Sapporo Medical University, School of Medicine, Sapporo, Japan.

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMedGoogle Scholar
  2. 2.
    Inoue M, Tsugane S (2005) Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419–424CrossRefPubMedGoogle Scholar
  3. 3.
    Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(Suppl 2):ii31–ii36PubMedGoogle Scholar
  4. 4.
    Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3):49–58CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshida M, Ohtsu A, Boku N et al (2004) Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the japan clinical oncology group (JCOG) study. Jpn J Clin Oncol 34:654–659CrossRefPubMedGoogle Scholar
  6. 6.
    Shah MA, Schwartz GK (2004) Treatment of metastatic esophagus and gastric cancer. Semin Oncol 31:574–587CrossRefPubMedGoogle Scholar
  7. 7.
    Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). J Clin Oncol 21:54–59CrossRefPubMedGoogle Scholar
  8. 8.
    Dickson JL, Cunningham D (2004) Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 16:255–263CrossRefPubMedGoogle Scholar
  9. 9.
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720CrossRefPubMedGoogle Scholar
  10. 10.
    Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069CrossRefPubMedGoogle Scholar
  11. 11.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefPubMedGoogle Scholar
  12. 12.
    Ajani JA, Rodriquez W, Bodoky G et al (2009) Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. ASCO Annual Meeting Proceedings. J Clin Oncol 27:15s (abstr 4511)CrossRefGoogle Scholar
  13. 13.
    Einzig AI, Neuberg D, Remick SC et al (1996) Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol 13:87–93CrossRefPubMedGoogle Scholar
  14. 14.
    Sulkes A, Smyth J, Sessa C, EORTC Early Clinical Trials Group et al (1994) Docetaxel (taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70:380–383PubMedGoogle Scholar
  15. 15.
    Roth AD, Maibach R, Martinelli G, Swiss group for clinical cancer research (SAKK), and the European institute of oncology (EIO) et al (2000) Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301–306CrossRefPubMedGoogle Scholar
  16. 16.
    Thuss-Patience PC, Kretzschmar A, Repp M et al (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23:494–501CrossRefPubMedGoogle Scholar
  17. 17.
    Yamaguchi K, Shimamura T, Hyodo I et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803–1808CrossRefPubMedGoogle Scholar
  18. 18.
    Takayama T, Sato Y, Sagawa T et al (2007) Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97:851–856PubMedGoogle Scholar
  19. 19.
    Nishi M, Omori Y, Miwa Y (1999) Response assessment of chemotherapy and radiotherapy for gastric carcinoma part IV. Kanehara Shuppan, TokyoGoogle Scholar
  20. 20.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  21. 21.
    Kim NK, Park YS, Heo DS et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818CrossRefPubMedGoogle Scholar
  22. 22.
    Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the european organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 18:2648–2657PubMedGoogle Scholar
  23. 23.
    Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267PubMedGoogle Scholar
  24. 24.
    Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefPubMedGoogle Scholar
  25. 25.
    Chun JH, Kim HK, Lee JS et al (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188–194CrossRefPubMedGoogle Scholar
  26. 26.
    Boku N, Ohtsu A, Shimada Y et al (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323PubMedGoogle Scholar
  27. 27.
    Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450–1457CrossRefPubMedGoogle Scholar
  28. 28.
    Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 20:1435–1442CrossRefGoogle Scholar
  29. 29.
    Koizumi W, Tanabe S, Saigenji K et al (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207–2212CrossRefPubMedGoogle Scholar
  30. 30.
    Taguchi T, Sakata Y, Kanamaru R et al (1998) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese cooperative study group trial (group A). Gan To Kagaku Ryoho 25:1915–1924PubMedGoogle Scholar
  31. 31.
    Mai M, Sakata Y, Kanamaru R et al (1999) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho 26:487–496PubMedGoogle Scholar
  32. 32.
    Yoshida K, Ninomiya M, Takakura N et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402–3407CrossRefPubMedGoogle Scholar
  33. 33.
    Ajani JA, Fodor MB, Tjulandin SA et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660–5667CrossRefPubMedGoogle Scholar
  34. 34.
    Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403CrossRefPubMedGoogle Scholar
  35. 35.
    Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256–264CrossRefPubMedGoogle Scholar
  36. 36.
    Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004CrossRefPubMedGoogle Scholar
  37. 37.
    De Vita F, Orditura M, Matano E et al (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92:1644–1649CrossRefPubMedGoogle Scholar
  38. 38.
    Nakajima T, Ota K, Ishihara S et al (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208CrossRefPubMedGoogle Scholar
  39. 39.
    Gallardo-Rincon D, Onate-Ocana LF, Calderillo-Ruiz G (2000) Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 7:45–50CrossRefPubMedGoogle Scholar
  40. 40.
    Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991–4997CrossRefPubMedGoogle Scholar
  41. 41.
    van Groeningen CJ, Godefridus J, Peters J et al (2000) Phase I clinical and pharmacokinetic study of S-1 in advanced solid tumors. J Clin Oncol 18:2772–2779PubMedGoogle Scholar
  42. 42.
    Ajani JA, Faust J, Ikeda K et al (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957–6965CrossRefPubMedGoogle Scholar
  43. 43.
    Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221–231CrossRefPubMedGoogle Scholar
  44. 44.
    Sym SJ, Chang HM, Ryu MH et al. (2009) Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 26 (Epub ahead of print)Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Yasushi Sato
    • 1
  • Tetsuji Takayama
    • 2
  • Tamotsu Sagawa
    • 1
  • Yasuo Takahashi
    • 3
  • Hiroyuki Ohnuma
    • 3
  • Syunichi Okubo
    • 3
  • Naoaki Shintani
    • 3
  • Shingo Tanaka
    • 1
  • Masaya Kida
    • 4
  • Yasuhiro Sato
    • 5
  • Hidetoshi Ohta
    • 5
  • Koji Miyanishi
    • 1
  • Tsutomu Sato
    • 1
  • Rishu Takimoto
    • 1
  • Masayoshi Kobune
    • 1
  • Koji Yamaguchi
    • 6
  • Koichi Hirata
    • 6
  • Yoshiro Niitsu
    • 7
  • Junji Kato
    • 1
  1. 1.Fourth Department of Internal Medicine, School of MedicineSapporo Medical UniversitySapporoJapan
  2. 2.Department of Gastroenterology and OncologyTokushima UniversityTokushimaJapan
  3. 3.Department of GastroenterologyHokkaido Cancer CenterSapporoJapan
  4. 4.Department of GastroenterologyChitose City HospitalChitoseJapan
  5. 5.Department of GastroenterologyOji General HospitalTomakomaiJapan
  6. 6.First Department of Surgery, School of MedicineSapporo Medical UniversitySapporoJapan
  7. 7.Department of Molecular Target Exploration, School of MedicineSapporo Medical UniversitySapporoJapan

Personalised recommendations